Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid

Figure 2

BMD (mean ± SD; g/m²) of lumbar spine (a) and femur hip (b) after treatment with zoledronic acid.

(a) Lumbar spine: baseline 0.97 (±0.15), 1 year 1.04 (±0.18), 2 years 1.10 (±0.18)

(b) Femur hip: baseline 0.82 (±0.10), 1 year 0.87 (±0.11), 2 years 0.91 (±0.10)